1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor

P2Y Receptor

P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose. To date, 12 P2Y receptors have been cloned in humans: P2Y1, P2Y2, P2Y4, P2Y5, P2Y6, P2Y8, P2Y9, P2Y10, P2Y11, P2Y12, P2Y13 and P2Y14. P2Y receptors are present in almost all human tissues where they exert various biological functions based on their G-protein coupling. P2Y2 is a potential drug target for treating cystic fibrosis. P2Y11 is a regulator of immune response, and a common polymorphism carried by almost 20% of North European caucasians give increased risk of myocardial infarction, making P2Y11 an interesting drug target candidate for treatment of myocardial infarction. P2Y12 is the target of the anti-platelet drug clopidogrel and other thienopyridines.

P2Y Receptor Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-B0879A
    Suramin sodium salt Inhibitor 99.93%
    Suramin sodium salt (Suramin hexasodium salt), a polysulfonated naphthylurea, is a potent competitive DNA topoisomerase II inhibitor with an IC50 of 5 μM. Suramin sodium salt inhibits IL-4 with an IC50 of 55-70 μM. Suramin sodium salt has antiproliferative, anticancer, and anti-HIV activities and prevents binding of a variety of growth factors to their respective receptors.
  • HY-17459
    Clopidogrel hydrogen sulfate Inhibitor
    Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
  • HY-10064
    Ticagrelor Antagonist 99.98%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-B0606
    Diquafosol tetrasodium Agonist 99.93%
    Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.
  • HY-13104
    MRS 2578 Antagonist
    MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors.
  • HY-118284
    Vicagrel Inhibitor
    Vicagrel, an acetate derivative of Clopidogrel, is a P2Y12 platelet inhibitor potentially for the treatment of thrombosis, the substrate of carboxylesterase 2 (CES2). Vicagrel demonstrates a favorable safety profile and excellent anti-platelet activity, which could be an anti-platelet drug and for the unmet medical needs of cardiovascular diseases.
  • HY-11021
    Elinogrel Antagonist >98.0%
    Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.
  • HY-13831
    BPTU Antagonist 98.03%
    BPTU is a novel P2Y1 allosteric antagonist.
  • HY-15284
    Prasugrel Inhibitor >98.0%
    Prasugrel (PCR 4099) is a platelet inhibitor with IC50 value of 1.8 μM.
  • HY-15799
    AZD1283 Antagonist 99.11%
    AZD1283 is a potent antagonist of the P2Y12 receptor with EC50 of 3.0 ug/kg/min, TI >10; with binding IC50 of 11 nM.
  • HY-18775
    N6-(4-Hydroxybenzyl)adenosine Inhibitor 99.66%
    N6-(4-Hydroxybenzyl)adenosine is a inhibitor of platelet aggregation induced in vitro by collagen and their activity range was demonstrated (IC50: 6.77-141 μM).
  • HY-15876
    Clopidogrel thiolactone Inhibitor >98.0%
    Clopidogrel thiolactone is a P2Y12 receptor inhibitor, is a potent antiplatelet agent.
  • HY-B0879
    Suramin Inhibitor
    Suramin, a polysulfonated naphthylurea, is a potent competitive DNA topoisomerase II inhibitor with an IC50 of 5 μM. Suramin inhibits IL-4 with an IC50 of 55-70 μM. Suramin has antiproliferative, anticancer, and anti-HIV activities and prevents binding of a variety of growth factors to their respective receptors.
  • HY-15284A
    Prasugrel hydrochloride Inhibitor 99.57%
    Prasugrel hydrochloride (PCR 4099 hydrochloride) is a platelet inhibitor with IC50 value of 1.8 μM.
  • HY-15283
    Clopidogrel Inhibitor
    Clopidogrel is a well-known and orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-111755
    Oral antiplatelet agent 1 Antagonist
    Oral antiplatelet agent 1 is a potent antiplatelet agent with an IC50 of 2.94 μM in vitro as well as antithrombotic efficacy in a rat model. P2Y receptor antagonist.
  • HY-100254
    TAK-024 Inhibitor
    TAK-024 is a platelet inhibitor with IC50s of 31, 79 and 51 nM in human, monkey and guinea pig, respectively.
  • HY-15284B
    Prasugrel (Maleic acid) Inhibitor
    Prasugrel (PCR 4099) Maleic acid is a platelet inhibitor with IC50 value of 1.8 μM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.